Month: September 2026

Reproductive Health Care Post-Roe (2025-2026)

Duke University Hospital’s unique geography (North Carolina is the furthest southern state now permitting abortion care), along with its institutional structure (private rather than public), make it an ideal place to examine access to reproductive healthcare. This project documented the medical, ethical and political conditions of the post-Roe landscape as seen from the viewpoints and experiences of reproductive care providers.
Read More

2026 Young People’s Reproductive Justice Policy Agenda

Young people today—a majority of whom are Black, Indigenous, Asian American, Native Hawaiian, Pacific Islander, or Latinx/a—are on the frontlines of the fight for Reproductive Justice: organizing, educating, shifting culture, and building power with URGE. URGE envisions a liberated world where we can live with justice, love freely, express our gender and sexuality, and define and create families of our choosing.
Read More

Reproductive Freedom for All Slams Fifth Circuit Case That Threatens Mifepristone Access Nationwide Ahead of Oral Arguments

The U.S. Court of Appeals for the Fifth Circuit will hear oral arguments in Louisiana v. U.S. Food and Drug Administration (FDA), a lawsuit seeking to end mail and pharmacy access to mifepristone nationwide—including in states where abortion is protected.
Read More

Guttmacher Institute Announces 2026–2029 Strategic Plan to Meet Urgent Challenges Facing Sexual and Reproductive Health and Rights

The Guttmacher Institute today announced its 2026–2029 Strategic Plan, a focused roadmap for strengthening the Institute’s role as a trusted source of evidence and action at a time of profound threats to sexual and reproductive health and rights (SRHR) in the United States and around the world.
Read More

Virginia District Court Rules FDA Unlawfully Restricted Abortion Pill Access

A Virginia district court judge ordered the FDA to reconsider its restrictions on mifepristone, a highly safe and effective prescription medication for terminating early pregnancy. The judge, Robert S. Ballou, sided with reproductive health clinics in three states that argued that current restrictions are excessive, medically unnecessary, and inconsistent with federal law. The challenged restrictions are part of FDA’s 2023 risk evaluation mitigation strategy (2023 REMS).
Read More

Health Care Financing to Improve Availability of Affordable Contraception: Identifying Promising Practices

Effective family planning that meets an individual’s needs, values, and preferences is a critical element of high-quality health care for women. Despite the well-documented role of family planning in improving maternal and infant health outcomes, persistent financial obstacles create barriers to care for many women. An ad hoc committee of the National Academies of Sciences, Engineering, and Medicine will review programs that aim to improve availability and affordability of contraception and identify effective strategies to inform future policy and practice.
Read More
No widgets found. Go to Widget page and add the widget in Offcanvas Sidebar Widget Area.